Valeritas Holdings Inc (NASDAQ:VLRX)has a wearable insulin delivery device and a recent study showed a positive trajectory. The V-Go device showed that patients who switched from pens and syringes to VLRX’s device improved blood glucose and also lowered their dose of insulin.
VLRX CEO, John Timberlake, commented, “The largest study of V-Go patients to date has demonstrated that regardless of baseline insulin dose or duration of diabetes, patients who switched to V-Go significantly lowered their blood glucose. We believe that is significant for diabetes patients, their medical professionals, payors, and Valeritas.”Timberlake continued, “We recently reported our third consecutive quarter of record revenue which is a direct result of V-Go gaining momentum among patients with type 2 diabetes. V-Go is discreet, simple-to-use, cost-effective, clinically proven, and the only disposable, daily insulin delivery option.”
Valeritas Holdings Inc (NASDAQ:VLRX) is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients.
Find out when $VLRX reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to the press, The 283 patient, retrospective study demonstrated clinically and statistically significant reductions in A1C by over 1% (a measure of blood glucose control), and insulin total daily dose (TDD) at three and seven months. The percent of patients at high risk (A1C > 9%) was reduced by nearly 50% after switching to V-Go. In addition, over 50% of all patients in the study achieved an A1C less than 8%. “By improving glycemic control, our hope is to reduce rates of complications as well as decrease health care cost, which is a priority for all healthcare systems.” said lead author and endocrinologist RipuHundal, M.D., of First State Endocrinology in Newark, Delaware.
“Findings from the ENABLE Study demonstrated that no matter how long a patient had been diagnosed with diabetes, switching to V-Go from insulin delivery via insulin pens and syringes resulted in significantly lower A1C levels,” said lead author, Jane Cases, M.D., of Marietta, Ohio.
Valeritas Holdings Inc (NASDAQ: VLRX) is up over 11% over the last month. The stock took a healthy jump this morning on the study’s findings. VLRX has a market cap of $43.73M and a float of 1.63M. The company has solid evidence under their belt to prove the legitimacy of their insulin delivery system. With this kind of attention, potential investors need to be watching closely here as this one could be moving fast. Sign-up for continuing coverage on shares of $VLRX stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $VLRX, either long or short, and we have not been compensated for this article.